Table 2.
Univariable analysis for RFS in 251 P‐SCLC and 46 C‐SCLC patients
| P‐SCLC | C‐SCLC | |||||
|---|---|---|---|---|---|---|
| Clinical factors | (n = 251) | Five‐year RFS% | P‐value | (n = 46) | Five‐year RFS% | P‐value |
| Gender | ||||||
| Male | 175 (69.7) | 46.5 | 0.006 * | 35 (76.1) | 49.7 | 0.647 |
| Female | 76 (30.2) | 65.7 | 11 (23.9) | 39.8 | ||
| Age | ||||||
| ≤60 years | 164 (65.3) | 52.5 | 0.688 | 24 (52.2) | 48.7 | 0.653 |
| >60 years | 87 (34.7) | 54.4 | 22 (47.8) | 47.8 | ||
| Smoking history | ||||||
| Yes | 159 (63.3) | 47.1 | 0.033 * | 36 (78.3) | 45.0 | 0.463 |
| No | 92 (36.6) | 61.4 | 10 (21.7) | 60.0 | ||
| Tumor laterality | ||||||
| Left | 126 (50.1) | 52.8 | 0.691 | 20 (43.5) | 44.1 | 0.536 |
| Right | 125 (49.8) | 52.2 | 26 (56.5) | 49.7 | ||
| VALSG staging | ||||||
| Limited | 242 (96.4) | 52.9 | 0.183 | 44 (95.7) | 48.8 | 0.112 |
| Extensive | 9 (3.2) | 41.7 | 2 (4.3) | 0.0 | ||
| AJCC seventh staging | ||||||
| I | 78 (31.1) | 72.9 | <0.001 * | 9 (19.6) | 87.5 | 0.103 |
| II | 70 (27.9) | 56.0 | 15 (32.6) | 27.2 | ||
| III | 95 (37.8) | 34.7 | 20 (43.5) | 45.0 | ||
| IV | 8 (3.2) | 46.9 | 2 (4.3) | 0.0 | ||
| Lymph node metastasis | ||||||
| Yes | 153 (61.0) | 43.0 | <0.001 * | 30 (65.2) | 34.7 | 0.031 * |
| No | 98 (39.0) | 68.0 | 16 (34.8) | 79.1 | ||
| Extent of resection † | ||||||
| Lobectomy | 200 (79.7) | 56.5 | 0.012 * | 36 (78.3) | 58.0 | 0.012 * |
| Sublobectomy | 15 (6.0) | 50.9 | 4 (8.7) | 25.0 | ||
| Pneumonectomy | 18 (7.2) | 41.3 | 2 (4.3) | 0.0 | ||
| Treatment mode | ||||||
| S | 32 (12.7) | 66.8 | 0.007 * | 3 (6.5) | 50.0 | 0.827 |
| S + CTx | 140 (55.8) | 56.0 | 26 (56.5) | 51.7 | ||
| S + CTx + RT | 79 (31.5) | 41.0 | 17 (37) | 41.2 | ||
| Chemo‐regmen ‡ | ||||||
| SCLC regimen | 150 (59.8) | 44.2 | 0.940 | 17 (37) | 55.0 | 0.980 |
| NSCLC regimen | 0 (0.0) | — | 9 (19.6) | 50.0 | ||
| SCLC+NSCLC regimen | 3 (1.2) | 33.3 | 4 (8.7) | 33.3 | ||
| No chemotherapy | 32 (12.7) | 66.8 | 3 (6.5) | 50 | ||
| PCI | ||||||
| Yes | 59 (23.5) | 58.9 | 0.267 | 7 (15.2) | 57.1 | 0.752 |
| No | 192 (76.5) | 50.5 | 39 (84.8) | 46.0 | ||
AJCC, American Joint Committee on Cancer; C‐SCLC, combined small cell lung cancer; CTx, chemotherapy; PCI, prophylactic cranial irradiation; P‐SCLC, pure small cell lung cancer; RFS, recurrence‐free survival; RT, radiotherapy; S, surgery; VALSG, Veterans Administration Lung Study Group.
†
18 and four patients with P‐SCLC and C‐SCLC respectively were excluded because the surgical information was unavailable.
‡
66 and 13 patients with P‐SCLC and C‐SCLC were excluded respectively because the chemotherapy regimen was unknown.
*
P < 0.05 is indicated by bold italics.